Low-dose methotrexate results in the selective accumulation of aminoimidazole carboxamide ribotide in an erythroblastoid cell line

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 1, 2013, Pages 154-163

  Funk, Ryan S ^a   Van Haandel, Leon ^a   Becker, Mara L ^a,b   Steven Leeder, J ^a,b,c  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b Schools of Medicine   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXYURIDINE 5' MONOPHOSPHATE DISODIUM SALT; 5 AMINOIMIDAZOLE 4 CARBOXAMIDE 1 BETA DEXTRO RIBOFURANOSYL 5' MONOPHOSPHATE; BIOLOGICAL MARKER; CHEMICAL COMPOUND; DIHYDROFOLIC ACID; METHOTREXATE; PHOSPHORIBOSYLAMINOIMIDAZOLECARBOXAMIDE FORMYLTRANSFERASE; POLYGLUTAMIC ACID; PYRIMIDINE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; BIOACCUMULATION; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; DRUG UPTAKE; ERYTHROBLASTOID CELL; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; PRIORITY JOURNAL;

AMINOIMIDAZOLE CARBOXAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROBLASTS; FOLIC ACID ANTAGONISTS; HUMANS; K562 CELLS; METHOTREXATE; RIBONUCLEOTIDES;

EID: 84884607430     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.206672     Document Type: Article

References (53)

1. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, and Jolivet J (1985a) Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260:9720-9726.
2. Allegra CJ, Drake JC, Jolivet J, and Chabner BA (1985b) Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 82:4881-4885.
3. Allegra CJ, Hoang K, Yeh GC, Drake JC, and Baram J (1987) Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem 262:13520-13526.
4. Andersson LC, Nilsson K, and Gahmberg CG (1979) K562-a human erythroleukemic cell line. Int J Cancer 23:143-147.
5. Baggott JE and Morgan SL (2007) Methotrexate and erythro-9-(2-hydroxynon- 3-yl) adenine therapy for rat adjuvant arthritis and the effect of methotrexate on in vivo purine metabolism. Eur J Pharm Sci 31:95-101.
6. Baggott JE, Morgan SL, Ha TS, Alarcón GS, Koopman WJ, and Krumdieck CL (1993) Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol 11 (Suppl 8):S101-S105.
7. Baggott JE, Morgan SL, and Koopman WJ (1998) The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion. Arthritis Rheum 41:1407-1410.
8. Baggott JE, Morgan SL, Sams WM, and Linden J (1999) Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Arch Dermatol 135:813-817.
9. Baggott JE, Vaughn WH, and Hudson BB (1986) Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 59-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 236:193-200.
10. Baram J, Chabner BA, Drake JC, Fitzhugh AL, Sholar PW, and Allegra CJ (1988) Identification and biochemical properties of 10-formyldihydrofolate, a novel folate found in methotrexate-treated cells. J Biol Chem 263:7105-7111.
11. Becker ML, Rosé CD, Cron RQ, Sherry DD, Bilker WB, and Lautenbach E (2010) Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens. J Rheumatol 37:870-875.
12. Beckers A, Organe S, Timmermans L, Vanderhoydonc F, Deboel L, Derua R, Waelkens E, Brusselmans K, Verhoeven G, and Swinnen JV (2006) Methotrexate enhances the antianabolic and antiproliferative effects of 5-aminoimidazole-4- carboxamide riboside. Mol Cancer Ther 5:2211-2217.
13. Borsa J and Whitmore GF (1969a) Studies relating to the mode of action of methotrexate. 3. Inhibition of thymidylate synthetase in tissue culture cells and in cellfree systems. Mol Pharmacol 5:318-332.
14. Borsa J and Whitmore GF (1969b) Studies relating to the mode of action of methotrexate. II. Studies on sites of action in L-cells in vitro. Mol Pharmacol 5:303-317.
15. Chan ES and Cronstein BN (2010) Methotrexate-how does it really work? Nat Rev Rheumatol 6:175-178.
16. Chu E, Drake JC, Boarman D, Baram J, and Allegra CJ (1990) Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells. J Biol Chem 265:8470-8478.
17. Cronstein BN, Eberle MA, Gruber HE, and Levin RI (1991) Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 88:2441-2445.
18. Cronstein BN, Naime D, and Ostad E (1993) The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 92:2675-2682.
19. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J, and Kremer J (2005) Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 64:1180-1185.
20. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, and Kremer J (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50:2766-2774.
21. Dolezalová P, Krijt J, Chládek J, Nemcová D, and Hoza J (2005) Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis. Rheumatology (Oxford) 44:74-79.
22. Drake JC, Allegra CJ, Baram J, Kaufman BT, and Chabner BA (1987) Effects on dihydrofolate reductase of methotrexate metabolites and intracellular folates formed following methotrexate exposure of human breast cancer cells. Biochem Pharmacol 36:2416-2418.
23. Fairbanks LD, Rückemann K, Qiu Y, Hawrylowicz CM, Richards DF, Swaminathan R, Kirschbaum B, and Simmonds HA (1999) Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem J 342:143-152.
24. Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, and Zummer M; Canadian Network For Improved Outcomes in Systemic Lupus (2008) Steroidsparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 59:1796-1804.
25. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, and Revillard JP (1998) Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 102:322-328.
26. Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, and Zemel LS; The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med 326:1043-1049.
27. Goldman ID (1974) The mechanism of action of methotrexate. I. Interaction with a low-affinity intracellular site required for maximum inhibition of deoxyribonucleic acid synthesis in L-cell mouse fibroblasts. Mol Pharmacol 10:257-274.
28. Halilova KI, Brown EE, Morgan SL, Bridges SL, Jr, Hwang MH, Arnett DK, and Danila MI (2012) Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int J Rheumatol 2012:978396.
29. Hobl EL, Jilma B, Erlacher L, Duhm B, Mustak M, Bröll H, Högger P, Rizovski B, and Mader RM (2012) A short-chain methotrexate polyglutamate as outcome parameter in rheumatoid arthritis patients receiving methotrexate. Clin Exp Rheumatol 30:156-163.
30. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, and Valdimarsson H (2005) The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 114:154-163.
31. Jolivet J, Schilsky RL, Bailey BD, Drake JC, and Chabner BA (1982) Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. J Clin Invest 70:351-360.
32. Kalb RE, Strober B, Weinstein G, and Lebwohl M (2009) Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 60:824-837.
33. Katerelos M, Mudge SJ, Stapleton D, Auwardt RB, Fraser SA, Chen CG, Kemp BE, and Power DA (2010) 5-aminoimidazole-4-carboxamide ribonucleoside and AMPactivated protein kinase inhibit signalling through NF-κB. Immunol Cell Biol 88: 754-760.
34. Koizumi S (1988) Impairment of methotrexate (MTX)-polyglutamate formation of MTX-resistant K562 cell lines. Jpn J Cancer Res 79:1230-1237.
35. Kremer JM, Galivan J, Streckfuss A, and Kamen B (1986) Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 29: 832-835.
36. Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, and Dhillon V (2004) Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum 50:364-371.
37. Lyons SD and Christopherson RI (1991) Antifolates induce primary inhibition of the de novo purine pathway prior to 5-aminoimidazole-4-carboxamide ribotide transformylase in leukemia cells. Biochem Int 24:187-197.
38. Matherly LH, Czajkowski CA, and Angeles SM (1991) Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport. Cancer Res 51:3420-3426.
39. Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, Carlin G, Huie MA, and Cronstein BN (1998) Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-59- nucleotidasemediated conversion of adenine nucleotides. J Clin Invest 101:295-300.
40. Morgan SL, Oster RA, Lee JY, Alarcón GS, and Baggott JE (2004) The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheum 50:3104-3111.
41. Pinedo HM, Zaharko DS, Bull JM, and Chabner BA (1976) The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res 36:4418-4424.
42. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, Dolezalova P, Alessio M, Burgos-Vargas R, and Corona F, et al.; Pediatric Rheumatology International Trials Organization (2004) A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50:2191-2201.
43. Sant ME, Lyons SD, Phillips L, and Christopherson RI (1992) Antifolates induce inhibition of amido phosphoribosyltransferase in leukemia cells. J Biol Chem 267: 11038-11045.
44. Smoleńska Z, Kaznowska Z, Zarówny D, Simmonds HA, and Smoleński RT (1999) Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatoid arthritis. Rheumatology (Oxford) 38:997-1002.
45. Taisun H and Baggott JE (1994) 5-aminoimidazole-4-carboxamide ribotide (AICAR) and its metabolites: metabolic and cytotoxic effects and accumulation during methotrexate treatment. J Nutr Biochem 5:522-528.
46. Urakawa K, Mihara M, Suzuki T, Kawamura A, Akamatsu K, Takeda Y, and Kamatani N (2000) Polyglutamation of antifolates is not required for induction of extracellular release of adenosine or expression of their anti-inflammatory effects. Immunopharmacology 48:137-144.
47. van Haandel L, Becker ML, Leeder JS, Williams TD, and Stobaugh JF (2009) A novel high-performance liquid chromatography/mass spectrometry method for improved selective and sensitive measurement of methotrexate polyglutamation status in human red blood cells. Rapid Commun Mass Spectrom 23:3693-3702.
48. van Haandel L, Becker ML, Williams TD, Leeder JS, and Stobaugh JF (2011) Measurement of methotrexate polyglutamates in human erythrocytes by ion-pair UPLC-MS/MS. Bioanalysis 3:2783-2796.
49. van Haandel L, Becker ML, Williams TD, Stobaugh JF, and Leeder JS (2012) Comprehensive quantitative measurement of folate polyglutamates in human erythrocytes by ion pairing ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 26:1617-1630.
50. Weinblatt ME (1985) Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol Suppl 12 (Suppl 12):35-39.
51. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, and Trentham DE (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818-822.
52. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, Wolfe F, Wall B, Anderson L, and Gall E, et al. (1994) Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 37:1492-1498.
53. You X, Williams A, Dervieux T, He W, and Cronstein BN (2013) Fibroblasts from methotrexate-sensitive mice accumulate methotrexate polyglutamates but those from methotrexate-resistant mice do not. Clin Exp Rheumatol 31:433-435.